Released Aug 8, 2023, after the close
10-Q filed Aug 9, 2023, 40 days after period end · 0001636422-23-000096
Q2 2023 · 10-Q
Revenue$73.21M$73.21M +3.7% vs Q2 2022−0.9% vs Q1 2023
Net Income-$32.61M-$32.61M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.58-$0.58 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$34,618,000N/M
Operating Cash Flowderived-$11,574,000N/M
Free Cash Flowderived-$11,981,000N/M
Margins · derived
Operating margin-47.3%−0.3 pt vs Q2 2022
Net margin-44.5%+2.8 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $73.21M | $70.63M | $59.63M | $43.26M |
| Net Income | -$32.61M | -$33.43M | -$35.83M | -$27.18M |
| EPS Diluted | -$0.58 | -$0.62 | -$0.80 | -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR